What were Zoetis's primary revenue drivers in 2017?

Zoetis's revenue drivers in 2017 included increased sales from its dermatology portfolio and new product launches, contributing approximately 7% to growth. The growth of its in-line products accounted for an additional 2%, with price and volume each contributing 1%. Product rationalizations as part of the operational efficiency initiative led to a 1% decline, which was partially offset by a 1% favorable impact from foreign exchange.

How did Zoetis manage its operational efficiency and supply chain?

Zoetis launched a comprehensive operational efficiency program in 2015, focusing on portfolio simplification, market approach changes, reducing presence in certain countries, and exiting manufacturing sites. As of December 31, 2017, approximately 2,600 positions had been eliminated through divestitures, attrition, and terminations. The company stated the program was substantially complete, with minor additional reductions expected.

What is Zoetis's strategy for future growth?

Zoetis's core growth strategies include leveraging its direct local presence and strong customer relationships, further penetrating emerging markets, pursuing new product R&D and product lifecycle innovation, remaining a partner of choice for new products and technologies, maintaining high-quality products and improving manufacturing margins, and expanding into complementary businesses like diagnostics and genetics.

What are the main risks identified by Zoetis in its 10-K filing?

Key risks identified include potential restrictions and bans on the use of antibacterials in food-producing animals, perceptions of adverse human health effects from animal products, unanticipated safety or efficacy concerns with its products, increased regulation in the livestock industry, disease outbreaks, customer and distributor consolidation, weather conditions, global economic downturns, patent expirations, competitive pressures (including generics), and risks related to international operations (e.g., currency fluctuations, political instability).

ZTS 10-K FY2017 Annual Report — Revenue, Net Income, EPS

Summary

Zoetis Inc. reported strong performance in its 2017 10-K filing, showcasing robust revenue growth driven by both its U.S. and International segments. The company's strategic focus on product innovation and lifecycle management, particularly in key product lines like Apoquel® and the ceftiofur line, has yielded positive results. Zoetis continues to invest in research and development to maintain its leadership in the animal health market. The company's operational efficiency program is largely complete, contributing to improved cost management. Financially, Zoetis demonstrated solid revenue growth and healthy net income. The company successfully managed its debt levels and continued its commitment to shareholder returns through dividends and share repurchases. While facing industry-wide challenges such as regulatory changes and competition, Zoetis' diversified portfolio across livestock and companion animals, coupled with its global reach, positions it well for continued success in the evolving animal health landscape.

Financial Highlights

56 data points

Beta

Revenue

$5.31B

0.7% Gross Margin

Net Income

$862.00M

0.2% Net Margin

EPS (Diluted)

$1.75

Total Assets

$8.59B

Cash & Equivalents

$1.56B

Free Cash Flow

$1.12B

Financial Statements

Beta

Revenue	$5.31B
Cost of Revenue	$1.77B
Gross Profit	$3.53B
SG&A Expenses	$1.33B
Interest Expense	$175.00M
Net Income	$862.00M
EPS (Basic)	$1.76
EPS (Diluted)	$1.75
Shares Outstanding (Basic)	489.92M
Shares Outstanding (Diluted)	493.16M

Key Highlights

1Total revenue increased by 9% to $5.3 billion in 2017, with operational revenue growth of 8% excluding foreign exchange impacts.
2Both U.S. and International segments reported revenue growth, with the International segment experiencing an 11% increase (10% operationally).
3Companion animal products saw significant growth (14%), outpacing livestock products (5%), driven by key brands like Apoquel®.
4Research and Development (R&D) expenses increased by 2% to $382 million, reflecting continued investment in innovation.
5Net income attributable to Zoetis increased by 5% to $864 million, while diluted earnings per share grew to $1.75.
6The company repurchased approximately 8 million shares under its $1.5 billion repurchase program, with about $1 billion remaining at year-end 2017.
7Zoetis's operational efficiency program is substantially complete, having eliminated approximately 2,600 positions as of December 31, 2017.

Zoetis Inc. Annual Report, Year Ended Dec 31, 2017

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions